ALERTS, CHARTS, & HOT STOCKS

[BlazingStocks]

$FAVO - recognized by Global Finance for the Best Fixed Income Investment Innovation Award as part of their Annual Top Innovation in Finance Awards for 2024.
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html

[Singhania]

$CRDL - After a big breakout in yesterday’s session, I will not be surprised if we hit $3 in the next 2-3 sessions. Moreover, yesterday the stock made a multi-month high on unusual volume. May be smart people are accumulating before the FDA decision in June?

If the FDA news is favorable, then the sky is the limit, and we could see a massive jump that may take it to near $7-8. $CRDL must be on your watchlist.

[Singhania]

Analysts Think $CRDL is Undervalued

Last week, Canaccord Genuity lifted the PT to $8 from $6 on Cardiol Therapeutics Inc (NASDAQ: CRDL) – Potential gain of 260% from CMP.

Analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and with a PT of $9.

Moreover, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.

$RSLS $MRNA $NVAX $INSM $KTRA $VTYX $SCPX

[Singhania]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174504600

[Singhania]

$MMA’s Hype Acquisition Targets 640 Million Potential Participants

Alta Global Group (NYSE American:MMA) announced its strategic acquisition of Hype for. Hype is a subscription-based mobile marketing platform designed to help small businesses grow in today's age of social media.

Hype's software platform strengthens Alta's vision to convert 640 million MMA fans to participants by providing invaluable tools to our gym owner, coach, and athlete partners to not only grow their revenues, but also operate more efficiently, save costs and enhance the offerings to their members and community.

This acquisition is expected to accelerate Alta's technology roadmap, bringing forward new subscription revenue opportunities to Alta, whilst creating cost synergies by materially reducing product development overhead and bringing valuable technology expertise, skills and talent into the business.

Hype has processed over $40 million in payments through its platform, collected over 4 million contacts for current and previous customers, and generates revenue from recurring subscriptions and payment processing fees.

[ProfitScout]

$GV News: GV Announces Cooperation with CICC

TORONTO, May 22, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the Company's subordinate Farvision Career Education Group Inc signed a cooperation agreement with Canadian International Career College to explore the market in Asia on May 9,2024.

As Canada's aging population continues to rise, the government has implemented various measures to address the issue by attracting foreign workers to the PSWs sector. According to the Canadian Association of Senior Housing and Care Providers, the healthcare sector contributes over CA$100 billion to the Canadian economy each year.

The shortage of labor has resulted in a critical need for foreign workers in the personal support worker (PSW) field to fill the workforce gap and provide essential care and support to seniors and individuals with disabilities.

In addition to the economic benefits, the influx of foreign labor as PSWs also has a positive impact on the Canadian healthcare system. PSWs often serve as the primary caregivers for seniors and individuals with disabilities, playing a crucial role in assisting them with daily activities and maintaining their independence.

The courses offered by the Canadian International Career College (CICC) include Personal Support Worker Certificate, Medication Administration for PSW Certificate Course, Early Childcare Assistant (ECA) Diploma Course, Intensive Care Unit (ICU) Program for Nurse Certificate Course, Medical Surgical Certificate Course, CPR/AED Certificate Course, Standard First Aid with CPR Course, and Business Programs.

After completing all courses and passing exams, Farvision Career Education Group and CICC will assist students in obtaining work visas and provide job referrals. For local Chinese students, they can complete remote courses in China and receive certificates recognized by both China and the province of Ontario, Canada, upon passing exams.

This project will bring a new revenue growth point to the Company.

About Visionary Holdings Inc.

Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
[e-mail]

Cision View original content:https://www.prnewswire.com/news-releases/gv-announces-cooperation-with-cicc-302152260.html

SOURCE Visionary Holdings Inc.

[Singhania]

VVPR May See Action Soon – Major Business Update

VivoPower International PLC (NASDAQ: VVPR) is an international battery technology, electric vehicle, solar, and critical power services company whose core purpose is to deliver sustainable energy solutions to its customers.

Key Takeaways

Recently, Executive Chairman and CEO, Kevin Chin, increased his shareholding in the Company by a net total of 100,000 shares, approximately 2.7% of the undiluted number of issued and outstanding shares of the Company.

Investment commitment secured from private investment office backed by member of ruling Al Maktoum family of Dubai. Initial US$7.5m investment milestones previously met as part of US$10 million commitment. Tembo (subsidiary) has now met milestones to qualify for the final follow-on investment of US$2.5 million, for an aggregate total investment of US$10 million.

The stock is consolidating at the breakout point and may move towards $5, if sustain above $3.70. The stock had a big move in April when it went up $1.45 to $6.50. So it might fill that gap again to $9.90 from April.

[MRc2]

AGBA~ company tweet

As we come out of our quiet period next week, we want to express our commitment to delivering the best outcomes for our shareholders. Our teams have been working hard to ensure a smooth execution of the merger with AGBA/Triller. Stay tuned for further updates as we progress…

— Wing Fai Ng (@TheWingFai) May 23, 2024

[Singhania]

$MMA - Alta Global Group (MMA) On Watchlist After Big News- What do you think?
Alta Global Group Limited (NYSE American:MMA) stock might see notable buying interest after inking Strategic Partnership and Investment by Upper Management.

Here are major takeways for MMA investment thesis

Strategic Partnership and Investment by Upper Management - This partnership includes Upper Management becoming a shareholder of Alta Global Group. The partnership is expected to unlock a number of opportunities in the Mexican market including launching Alta's flagship Warrior Training Program at multiple gyms and developing content that can directly engage and monetize the 18.6m Mexican fans of UFC.

Earlier in May, $MMA announced announces its strategic acquisition of Hype for an undisclosed sum. . Hype reimagines the future of multiple product categories simultaneously across a $100 billion+ market for small business software. Hype has processed over $40 million in payments through its platform, helped businesses collect over 4 million contacts and is currently generating approximately $200,000 per annum in recurring revenue. Alongside Alta's existing product offering, the Hype products are expected to accelerate Alta's penetration into the substantial martial arts and combat sports market, with over 45,000 martial arts and combat sports academies in the US alone.

On May 10, The company announced its partnership with five-time MMA world champion Conor McGregor in support of Trainalta.com. McGregor, along with his long-standing coach and Alta Co-Founder John Kavanagh, has become a shareholder of Alta Global Group as it aims to convert 640 million MMA fans into active combat sports participants globally. Alta's network currently encompasses partnerships with over 500 gyms, representing a fraction of the total martial arts and combat sports gym landscape in the US, which stands at 45,000 establishments.

[BlazingStocks]

$AGBA News May 21, 2024

AGBA/Triller $4bn Merger: Excellent Progress Ahead of Plan
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore

[Singhania]

$MMA Links Huge Strategic Partnership and Investment by Upper Management
Alta Global Group (NYSE American:MMA) - The partnership is expected to unlock a number of opportunities in the Mexican market. The partnership is expected to unlock a number of opportunities in the Mexican market including launching Alta's flagship Warrior Training Program at multiple gyms and developing content that can directly engage and monetize the 18.6m Mexican fans of UFC.
This collaboration also marks a significant milestone in Alta's mission to broaden its reach and impact within the vibrant Mexican MMA community.Upper Management boasts a roster of top-tier talent, including renowned fighters such as Yair Rodriguez, former interim UFC featherweight Champion, Daniel Zellhuber, Ronaldo Rodriguez, Manuel Torres, Ignacio Bahamondes and Eric Silva. Through this partnership, Alta aims to leverage Upper Management's extensive network and expertise to tap into the burgeoning Mexican market for MMA enthusiasts and participants.
https://www.accesswire.com/865395/alta-global-group-announces-strategic-partnership-and-investment-by-upper-management-to-expand-its-presence-in-the-mexican-mma-market

[BlazingStocks]

$AGBA Article May 08, 2024

Triller CEO says deal with Bob Diamond-backed AGBA will revitalize social media push
https://www.axios.com/pro/media-deals/2024/05/08/triller-ceo-says-deal-with-bob-diamond-backed-agba-will-revitalize-social-media-push

[ProfitScout]

$GNPX: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024

Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations

AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).

"We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer."

"The Phase 1 dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase 2 expansion study," stated Mark Berger, M.D., Chief Medical Officer of Genprex. "The favorable results from our Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC) enabled us to shorten the Phase 1 portion of Acclaim-3. This should allow us to complete the Phase 1 portion of the study during the second half of 2024 and to advance more quickly into the Phase 2 expansion portion of Acclaim-3 in the second half of 2024. We look forward to providing study updates as we advance this potentially life-saving therapy to benefit patients battling ES-SCLC."

Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.

About the Acclaim-3 Clinical Trial
The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.

The Phase 1 dose escalation portion of the Acclaim-3 clinical study is expected to enroll up to 12 patients at approximately ten U.S. clinical sites to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.

The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.

Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for Reqorsa® Immunogene Therapy, in combination with Genentech, Inc's Tecentriq® in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.

About Reqorsa® Immunogene Therapy
Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid-based molecules in a lipoplex form (Genprex's Oncoprex® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. In addition, REQORSA disrupts the metabolism of cancer cells by decreasing glycolysis and ATP production in cancer cells with decreased TUSC2.

Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on current therapies for patients with NSCLC, SCLC, and possibly other cancers.

Tecentriq® is a registered trademark of Genentech, Inc.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]

[Zardiw]

$LIDR Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z

[TradeForProfits]

solid on $ABGA stuff. $BANT churning nicely 014's here after hitting .019 yesterday!

[BlazingStocks]

Yes, great $BANT News! MORE $AGBA information...

Article May 08, 2024

Triller CEO says deal with Bob Diamond-backed AGBA will revitalize social media push
https://www.axios.com/pro/media-deals/2024/05/08/triller-ceo-says-deal-with-bob-diamond-backed-agba-will-revitalize-social-media-push

[TradeForProfits]

good $AGBA news! U see $BANT $4.1M Government contract news today? https://finance.yahoo.com/news/bantecs-howco-awarded-4-19-140000243.html

[TradeForProfits]

$BANT awarded $4.19M US DoD contract news: https://finance.yahoo.com/news/bantecs-howco-awarded-4-19-140000243.html

[ProfitScout]

$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.

Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.

"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."

The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.

Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.

By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.

"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."

RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.

About Renovaro:

Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:

https://techbullion.com/avram-miller-talks-ab...es-with-ai

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

https://www.renovarogroup.com

https://www.renovarobio.com

https://www.renovarocube.com

About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.

https://www.cyclomics.com/

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: [e-mail]

Source: Renovaro Inc.

[BlazingStocks]

$AGBA - The $4 billion merger of AGBA and Triller announced on April 18, is a direct result of such team efforts. AGBA’s shares have traded well. As a result, we are pleased that AGBA has been informed by The Nasdaq Stock Market LLC ("Nasdaq") that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html

[TradeForProfits]

$BANT 'seek government approval for all Chem Flowtronic products' game changer right here for the company imo. https://finance.yahoo.com/news/bantec-engaged-letter-intent-acquire-140000970.html

[TradeForProfits]

$BANT acquisition & 50% increase in revs/profits Q1: https://finance.yahoo.com/quote/BANT

[BlazingStocks]

$PDGO News May 02, 2024

Paradigm Oil & Gas, Inc. (PDGO) Expands Market Presence with Proposed Strategic Oil and Gas Acquisitions
https://www.otcmarkets.com/stock/pdgo/news/Paradigm-Oil--Gas-Inc-PDGO-Expands-Market-Presence-with-Proposed-Strategic-Oil-and-Gas-Acquisitions?id=439005

[BlazingStocks]

$AGBA - The Merger represents a distinctive fusion of social media, content, fintech and healthtech, driven by the powerful AI capabilities of the Combined Group.
https://finance.yahoo.com/news/building-digital-economy-titan-agba-130000244.html

[TradeForProfits]

$BANT "note's conversion feature was removed" game changer imo. https://finance.yahoo.com/news/bantec-restated-senior-secured-note-140000380.html

[TradeForProfits]

$BANT 1m vol,acquisition 'sales of approximately $2.3 million and an EBITDA of $300,000' https://finance.yahoo.com/news/bantec-engaged-letter-intent-acquire-140000970.html

[TradeForProfits]

$BANT Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company

https://ih.advfn.com/stock-market/USOTC/bantec-pk-BANT/stock-news/93760809/bantec-engaged-in-a-letter-of-intent-to-acquire-a

[BlazingStocks]

$PDGO News December 28, 2023

Paradigm Oil And Gas, Inc. Announces Change in Control and Letter of Intent
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854

[TradeForProfits]

$BANT government purchases through HowCo subsidiary increasing. Revs up, profits up. https://finance.yahoo.com/news/bantec-reports-over-50-percent-140000631.html

[BlazingStocks]

Does the TikTok Ban Make Alphabet Stock a Buy?
https://www.fool.com/investing/2024/04/28/does-the-tiktok-ban-make-alphabet-stock-a-buy/

$AGBA $GOOG $META

[GlitteringSeeker16]

$STSN || Look at the OTCmarkets profile. New directors, just made filings to go Pink Current, and SAME address as former issuer. Last PR they had said they are pursuing acquisition in Green/Solar energy.

[BlazingStocks]

$WRIT News April 18, 2024

New Era in Blockchain Gaming: Writ Media Group, Inc. Announces Launch of Revolutionary NFT Minting Engine to Transform Esports, Gaming Tournaments, and Gaming Collectibles
https://www.otcmarkets.com/stock/WRIT/news/New-Era-in-Blockchain-Gaming-Writ-Media-Group-Inc-Announces-Launch-of-Revolutionary-NFT-Minting-Engine-to-Transform-Espo?id=437361

[BlazingStocks]

$AURI News April 16, 2024

Auri Inc. Announces New Business Development
https://finance.yahoo.com/news/auri-inc-announces-business-development-123500102.html

[BlazingStocks]

Looking for an update on Marketing results...

$AVRW

[BlazingStocks]

$PDGO News April 09, 2024

Paradigm Oil and Gas, Inc. announces its plans going forward.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241

[ProfitScout]

$AVRW is starting to climb now. High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below.

Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky

New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales

News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html

[BlazingStocks]

$PDGO News April 15, 2024

PDGO Announces Acquisition
https://www.otcmarkets.com/stock/PDGO/news/PDGO-Announces-Acquisition?id=436678

[Frankiy]

$IZM grabbing it as longest it is below $5 should pay out bigtime imo.

[BlazingStocks]

$PDGO - In connection with the previously announced change in control, the new management of PDGO has commenced the process of identifying and initiating targeted acquisitions for PDGO.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241

[BlazingStocks]

About $AGBA Group:
Established in 1993, AGBA Group Holding Limited (NASDAQ: AGBA) is a leading one-stop financial supermarket based in Hong Kong offering the broadest set of financial services and healthcare products in the Guangdong-Hong Kong-Macao Greater Bay Area

[GlitteringSeeker16]

$STSN

[GlitteringSeeker16]

Look at the change on OTCmarkets for $STSN

[BlazingStocks]

$AGBA News February 27, 2024

AGBA Group is Positioned For Hong Kong's Rebounding Macro Environment with Business Refinements and Growth Strategies
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4

[BlazingStocks]

$VVPR News April 10, 2024

VIVOPOWER SECURES FULL US$10M INVESTMENT IN TEMBO FROM EMIRATES INVESTMENT OFFICE
https://finance.yahoo.com/news/vivopower-secures-full-us-10m-111500807.html

[ProfitScout]

$IVDN News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth

PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.

Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”

About Innovative Designs, Inc.

Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.

Disclaimer

Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.

CONTACT:

Innovative Designs, Inc.

Joseph Riccelli, CEO
412-799-0350
[e-mail]
Website: http://www.insultexhousewrap.com

Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html

[FinlayS00]

Exciting news from iQSTEL - $IQST! They just hit record-breaking revenue of $50M+ in Q1 FY-2024, even before counting their latest acquisition. With plans for explosive growth and a focus on essential services like telecom, fintech, EVs, and the metaverse, this stock is on fire! Keep it on your radar!

https://www.prnewswire.com/news-releases/iqst--iqstel-q1-record-breaking-revenue-exceeds-50m-not-including-recent-acquisition-302114251.html

[BlazingStocks]

$VVPR News April 10, 2024

VIVOPOWER SECURES FULL US$10M INVESTMENT IN TEMBO FROM EMIRATES INVESTMENT OFFICE
https://finance.yahoo.com/news/vivopower-secures-full-us-10m-111500807.html

[BlazingStocks]

$PDGO News April 09, 2024

Paradigm Oil and Gas, Inc. announces its plans going forward.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241

[BlazingStocks]

$PDGO updated Twitter, maybe a new website soon...

News December 28, 2023

Paradigm Oil And Gas, Inc. Announces Change in Control and Letter of Intent
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854

[ProfitScout]

$GVH -Experience Effortless E-commerce Shipping: Globavend Holdings Limited (NASDAQ:GVH) Tailored Solutions from Hong Kong to Your Doorstep in Australia & New Zealand!
Click here: https://axecapitalusa.com/gvh/

Welcome to the future of logistics with Globavend Holdings Limited (NASDAQ:GVH), where innovation meets opportunity in the bustling e-commerce landscape of Asia-Pacific. As pioneers in direct injection from Hong Kong & Southern China to Australia and New Zealand, we offer investors a gateway to a market projected to witness exponential growth. Our integrated cross-border logistics solutions ensure seamless parcel consolidation, air freight forwarding, and customs clearance, catering to the evolving needs of online businesses.

Strategic Expansion: With plans to establish ground transportation and customs clearance teams, we are poised to capture a significant market share.

Profitable Partnerships: As an IATA-accredited cargo agent with strong ties to top air freight carriers, we guarantee cost-effective solutions.

Robust Growth: Amidst a booming e-commerce market, our stable business model promises lucrative returns for investors seeking long-term opportunities.

Innovative Solutions: Our all-in-one shipping solution ensures operational efficiency and customer satisfaction, positioning us as industry leaders.

Invest in Globavend today and be part of a transformative journey reshaping the future of global logistics.